# Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions

> **NCT00833664** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Terbinafine HCl 250mg tablets
- **DRUG:** Lamisil® 250 mg Tablets

## Key facts

- **NCT ID:** NCT00833664
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833664, "Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00833664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*